読み込み中
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
前日終値
$7.38
+$0.06 · +0.82%
日中の時刻はETです。市場データは遅延する場合があります。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日中レンジ
現在 $7.38
52週レンジ
現在 $7.38
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
87
大幅な割安
センチメント
66
強気
リスク
60
やや高いリスク
モメンタム
42
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
日中レンジ
現在 $7.38
52週レンジ
現在 $7.38
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3.12億 USD | 4347.22万 USD | — | 6.54万 USD | 19.09万 USD |
| 売上原価 | 3596.1万 USD | 319.05万 USD | 20.56万 USD | 3734 USD | 14.89万 USD |
| 粗利益 | 2.76億 USD | 4028.16万 USD | −20.56万 USD | 6.17万 USD | 4.2万 USD |
| 研究開発 | 1933.3万 USD | 394.23万 USD | 1315.51万 USD | 1067.95万 USD | 1313.3万 USD |
| 販売・一般管理 | 3016.6万 USD | 5869.58万 USD | 3580.27万 USD | 2000.61万 USD | 1634.66万 USD |
| 営業費用 | 1.26億 USD | 6263.8万 USD | 4875.22万 USD | 3068.56万 USD | 2947.96万 USD |
| 受取利息 | 384.6万 USD | 257.88万 USD | 268.19万 USD | 32.6万 USD | 1.44万 USD |
| 支払利息 | 278.2万 USD | 3.64万 USD | 3.43万 USD | 2.65万 USD | 1.59万 USD |
| 減価償却費と償却費 | 1454.9万 USD | 31万 USD | 7.08万 USD | 8.46万 USD | 6.19万 USD |
| 営業利益 | 1.5億 USD | −2235.64万 USD | −4895.78万 USD | −3062.4万 USD | −2943.76万 USD |
| 純利益 | 1.63億 USD | −1793万 USD | −4633.92万 USD | −2970.17万 USD | −2821.02万 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$14.50
上昇余地（96.48%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1840.1万0.00%2.3兆 USD0.03%$381.94+0.63%
Avantis U.S. Small Cap Value ETFAVUV1660.7万0.05%308.51億 USD0.25%$119.64-0.41%
iShares Russell 2000 ETFIWM1450.55万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF697.56万0.01%954億 USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH563.29万1.22%4.62億 USD0.35%$64.65+1.60%
Pacer US Small Cap Cash Cows ETFCALF489.28万0.14%35.87億 USD0.59%$54.66-0.16%
Vanguard Russell 2000 ETFVTWO353.95万0.02%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA253.6万0.01%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIAvantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHPacer US Small Cap Cash Cows ETFCALFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
